Treatments for non-active secondary progressive multiple sclerosis remain scarce – tiziana life sciences' (nasdaq:tlsa) first-in-class foralumab is showing promise

London, uk / accesswire / april 17, 2023 / research is being done into whether there might be treatments that tackle multiple sclerosis (ms) through immunosuppression and a reduction of patient neuroinflammation. anti-cd3 monoclonal antibodies are treatments that seek to reduce inflammation in the body, but all these immunosuppressive drugs use either animal or humanized antibodies, which are less effective than fully human antibodies.
TLSA Ratings Summary
TLSA Quant Ranking